Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hydroxymethylglutaryl-coenzyme A reductase (HMG-CoA reductase) is a key enzyme in the mevalonate pathway, which is responsible for the biosynthesis of cholesterol and other important isoprenoids. It catalyzes the conversion of HMG-CoA to mevalonic acid, representing the rate-limiting step in cholesterol synthesis. The enzyme's central role in cholesterol biosynthesis makes it a primary target for statins—a class of drugs used to lower blood cholesterol by inhibiting this enzyme's function.
Inhibition of HMG-CoA reductase, reducing cholesterol synthesis
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hydroxymethylglutaryl-coenzyme A reductase (HMG-CoA reductase).